CAJ | 학술논문

目的研究FAS -670A/G基因多态与吉非替尼治疗敏感性及患者生存之间的关系.方法入组88例接受吉非替尼单药治疗的I IA-IV期非小细胞肺癌患者,分析FAS -670A/G基因多态与吉非替尼治疗的临床获益率及患者生存的相关性.结果 FAS -670A/G基因多态与全组患者临床获益率无关.AA、AG、GG患者的2年总生存率分别为49.2%、49.2%和28.7%,有显著差异(P=0.028)；携带A等位基因的患者,2年总生存率高于GG基因型患者,分别为49.3%和28.7%,有统计学意义(P=0.007).多因素预后分析显示病理类型(P=0.020,RR：2.466,95%CI：1.150-5.288)和FAS -670多态性(P=0.036,RR：0.503,95%CI：0.264-0.955)是独立的预后因素.结论促进肿瘤细胞凋亡是吉非替尼抗肿瘤作用的重要部分,FAS -670A/G基因多态可能成为吉非替尼治疗的进展期非小细胞肺癌患者生存的预测指标.
목적연구FAS -670A/G기인다태여길비체니치료민감성급환자생존지간적관계.방법입조88례접수길비체니단약치료적I IA-IV기비소세포폐암환자,분석FAS -670A/G기인다태여길비체니치료적림상획익솔급환자생존적상관성.결과 FAS -670A/G기인다태여전조환자림상획익솔무관.AA、AG、GG환자적2년총생존솔분별위49.2%、49.2%화28.7%,유현저차이(P=0.028)；휴대A등위기인적환자,2년총생존솔고우GG기인형환자,분별위49.3%화28.7%,유통계학의의(P=0.007).다인소예후분석현시병리류형(P=0.020,RR：2.466,95%CI：1.150-5.288)화FAS -670다태성(P=0.036,RR：0.503,95%CI：0.264-0.955)시독립적예후인소.결론촉진종류세포조망시길비체니항종류작용적중요부분,FAS -670A/G기인다태가능성위길비체니치료적진전기비소세포폐암환자생존적예측지표.
Objective To investigate the association between polymorphism in FAS -670A/G and the clinical benefit and outcome of advanced Non-Small-Cell Lung Cancer patients treated with gefitinib. Methods 88 patients with advanced NSCLC treated with gefitinib were enrolled. Polymerase chain reaction based restriction fragment length polymorphism assay was used to determine the genotypes. Results We found that FAS -670 AG+AA genotype carriers had a significantly longer overall survival time than GG genotype carriers (P=0.007 ). After the multi-variants’ cox regression analysis, pathological types (P=0.020,RR: 2.466, 95%CI: 1.150-5.288) and FAS -670 genotype (P=0.036,RR: 0.503, 95%CI: 0.264-0.955) were found to be independent prognostic factor for these patients. Conclusion FAS -670A/G could be predictor of survival for advanced NSCLC patients treated with gefitinib.